Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Fruquintinib With Sintilimab in Treating Refractory Metastatic Colorectal Cancer Patients With TMB(Tumor Mutation Burden)-High and Non-MSI(Microsatellite Instability)-High

NCT04695470 is registered in ClinicalTrials.gov with Aiping Zhou as lead sponsor.

NCT NCT04695470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04695470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Fruquintinib With Sintilimab in Treating Refractory Metastatic Colorectal Cancer Patients With TMB(Tumor Mutation Burden)-High and Non-MSI(Microsatellite Instability)-High
Lead sponsor
Aiping Zhou
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2020
Completion date
June 30, 2022
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer